Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review

Proteasome inhibitors (PIs) are the backbone of combination treatments for patients with multiple myeloma and AL amyloidosis, while also indicated in Waldenström’s macroglobulinemia and other malignancies. PIs act on proteasome peptidases, causing proteome instability due to accumulating aggregated,...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgiopoulos, Georgios, Makris, Nikolaos, Laina, Ageliki, Theodorakakou, Foteini, Briasoulis, Alexandros, Trougakos, Ioannis P., Dimopoulos, Meletios-Athanasios, Kastritis, Efstathios, Stamatelopoulos, Kimon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
State-of-the-Art Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982226/
https://www.ncbi.nlm.nih.gov/pubmed/36875897
http://dx.doi.org/10.1016/j.jaccao.2022.12.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982226/
https://www.ncbi.nlm.nih.gov/pubmed/36875897
http://dx.doi.org/10.1016/j.jaccao.2022.12.005

Ejemplares similares